Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Enbridge Inc (ENB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Enbridge Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.08 (market cap $8.04B), while Enbridge Inc trades at $56.23 (market cap $121.05B). The key difference: Enbridge Inc is far larger — about 15.1× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Enbridge Inc pays a 5.03% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | ENB | |
|---|---|---|
Market Cap | $8.04B | $121.05B |
Sector | Health | Energy |
52-Week High | $339.75 | $58.04 |
52-Week Low | $241.71 | $44.59 |
Enterprise Value | $7.85B | $201.85B |
Dividend Yield | — | 5.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Enbridge (ENB) trades at $55.07, up 0.75% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $65.19 billion in 2025, with net income of $7.49 billion, though it missed Q3 2025 EPS estimates. Analyst sentiment is balanced with a 48% buy rating, and the stock offers a dividend yield supported by over $28 billion in growth projects. Recent news highlights its role in energy infrastructure and AI-driven power demand.
Outlook is cautiously optimistic due to solid cash flow and dividend sustainability, but risks include high debt levels and sensitivity to energy markets. The stock presents a value opportunity for income-focused investors, with earnings on July 31, 2026, as a key near-term catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →
